The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment
SH Cheng, KY Tu, HH Lee - Oncology Reports, 2024 - spandidos-publications.com
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), is undoubtedly one of the
major breakthroughs in lung cancer research. Patient survival and prognosis have all been …
major breakthroughs in lung cancer research. Patient survival and prognosis have all been …
LncRNA KCNQ1OT1/miR-496/HMGB1 signaling axis promotes invasion and migration of non-small cell lung cancer cells
Y Wang, X Jiang, M Qu, J Liang, J Yang, R Sun - Biochemical Genetics, 2023 - Springer
Enhanced invasion and migration of non-small cell lung cancer (NSCLC) cells is the major
cause of metastasis and poor prognosis in NSCLC. This study was conducted to investigate …
cause of metastasis and poor prognosis in NSCLC. This study was conducted to investigate …
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE …
SM Christ, F Alongi, U Ricardi, M Scorsetti, L Livi… - Radiotherapy and …, 2024 - Elsevier
Background and introduction Optimal dose and fractionation in stereotactic body
radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim …
radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim …
Les maladies oligométastatiques: état actuel et perspectives dans les cancers bronchiques non à petites cellules
T Berghmans, M Brandão - Revue des Maladies Respiratoires, 2023 - Elsevier
Résumé Le concept de maladie oligométastatique a été introduit à la fin des années 1990
pour décrire une situation intermédiaire entre les tumeurs localement avancées et …
pour décrire une situation intermédiaire entre les tumeurs localement avancées et …